



Snowdome
Foundation™



Shaking up the world of blood cancer treatments



2024
Annual
Review





Mission

Snowdome's mission is to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives.

Vision

Our vision is to give every Australian blood cancer patient the best opportunity for a cure.

Our thanks go to:

The Taboo Group who worked tirelessly to bring this review to life and to photographer, Chris Budgeon who generously captured our people this year.

Snowdome honours the Country and Songlines of the traditional custodians of the land on which we conduct business, the Wurundjeri peoples of the Kulin Nation. We recognise their spiritual relationship and continuing connection to the land, waters and seas, and celebrate their unique wisdom and commitment to Country. We acknowledge and pay respect to their Elders, past and present.

Table of Contents

5	Message from the Chairman and Chief Executive	24	Cannon Family Travel Grants
6	Achievements and Year in Review	25	Environmental, Social and Governance Compliance
8	The Wilson Centre for Blood Cancer Genomics	26	Financials 2023-24
9	Epworth Centre for Immunotherapies and Snowdome Laboratories	30	Board of Directors
10	2024 Snowdome Fellowship	32	Executive
12	2024 Gunn Family Haematology Fellowship	33	Committees
13	International Partnerships and Collaborations	34	Partners & Collaborators
14	Australasian Lymphoma Alliance	36	A Legacy of Hope
16	Thanks to our Supporters	37	Dedication
18	Blood Cancer Researchers Delivering Hope	38	What's in a Name?
19	A Year of Exceptional Research Grant Awards		
20	Snowball 2024		
22	Snowdome Honorary Patron		
23	2024 Events		

Message from the Chairman and Chief Executive

It is our great privilege to share with you our 2024 Annual Review. An opportunity to reflect on the past year's accomplishments but also to reaffirm our commitment to the vision that drives our work.

Over the past year, we faced challenges, embraced opportunities and witnessed the significant impact of our collective efforts in the lives of Australian blood cancer patients.

This review celebrates our stories of success, showcases the delivery of our strategic priorities and explores ways we have strengthened our vision for the future.

Snowdome turned 14 this year and we are immensely proud that Snowdome continues to support researchers who are at the forefront of precision medicine; champion the adoption of next-generation treatments, including the revolution of harnessing a patient's own immune system through CAR T-cell therapy; fund innovative research and clinical trials; and agitate for change.

In 2024, we saw genomic testing output triple at the Wilson Centre for Blood Cancer Genomics when the achievement of a Medicare Benefits Schedule item number for subsidised testing across Australia went live. 35 stem cell transplants were conducted and the first CAR T-cell patient was treated at the Epworth Centre for Immunotherapies and Snowdome Laboratories (ECISL).

Snowdome granted \$2.3 million into new research projects including a world-first CAR T-cell clinical trial in lymphoma at ECISL and the establishment of a new fellowship embedded within this project investigating the important role the gut biome may have in the efficacy of CAR T-cell treatment. We were delighted to announce six new multi-year grant projects and led four new grant calls, including the 2024 Gunn Family Fellowship which was awarded to an early career researcher in Queensland looking to produce a vaccine for amyloidosis using the latest mRNA technology.

Our prestigious partnership with the Leukemia and Lymphoma Society in the USA continued to support exceptional international work from Australian researchers, with total investment now over \$10 million.

The Australasian Lymphoma Alliance once again saw notable growth in membership and now boasts 146 members across Asia Pacific who collectively advance blood cancer research and improve outcomes for lymphoma patients.

Our major fundraising dinner Snowball™, raised a phenomenal \$670,000 in October, supporting patient access to two new blood cancer treatments not yet subsidised by the Australian Government. We also introduced the new annual Snowdome Ladies Luncheon to showcase our trailblazing female researchers and clinicians for International Women's Day 2024.

None of the achievements of this year would have been possible without the dedication of our Board of Directors, Executive Team, the generosity and trust of our donors, every partner and supporter and the incredible Snowdome researchers and clinicians.

Thank you.




John Salvaris
John Salvaris
Chairman



Kirstee Macbeth
Kirstee Macbeth
Chief Executive

Since 2010,
Snowdome has:

In 2024,



The Wilson Centre for Blood Cancer Genomics



The Wilson Centre for Blood Cancer Genomics (the Centre) was established in 2017 with the support of the incredibly generous Wilson family, who have donated more than \$9million, allowing an additional \$8million to be secured through leveraged funding.

The Centre was founded to provide equitable access to genomic testing for Australian blood cancer patients, improving their diagnosis and prognosis from the outset.

The Wilson family's philanthropic investment has built an enduring legacy for Australians diagnosed with blood cancer and produced a remarkable array of outcomes in precision education, research and diagnostics:

- More than 2,600 Chronic Lymphocytic Leukaemia (CLL) tests and more than 6,500 genetic tests were funded by the Centre, improving our knowledge of blood malignancies and enabling more specialised and individualised treatment regimens.
- Awarded 7 fellowships.
- Enabled 10 research positions.
- Development of 142 research publications and 121 presentations.
- Over 21 local national and international collaborations to extend the reach of the Centre scientific discovery and learning across the world.

Impressively, this investment into genomic testing acted as the catalyst for genomic testing to become embedded as the standard of care in Australia.

In March 2023, the goal of affordable, universally accessed, best-practice healthcare was achieved by Australian federal funding subsidisation through the Medicare Benefits Schedule (MBS). In November 2023, every eligible Australian blood cancer patient could access a life-changing, subsidised genomic test

through the MBS. The output of the Centre increased significantly and by December 2024, over 20,000 genomic tests had been performed, resulting in clinical interventions that transformed treatment outcomes.

The Centre also undertakes cutting-edge research into blood cancer treatment resistance, personalised medicine and genomic sequencing of blood cancers, led by globally respected researchers. Evaluating innovative treatments and technologies keeps the Centre at the forefront of genomic diagnosis. Importantly, the Centre has built a world-leading position in the understanding of resistance to targeted therapies in lymphoid malignancy.

Alongside internal research, the Centre collaborates with local, national and international institutions to bring together the top experts in their field.

“Christine was fundamental to the establishment of the Centre and would be immensely proud of what it has achieved in such a short space of time. We are delighted to continue our support of such life-changing work,” said the Wilson family.



Epworth Centre for Immunotherapies and Snowdome Laboratories



The Epworth Centre for Immunotherapies and Snowdome Laboratories (ECISL) continues to accelerate immunotherapy treatments.

The ECISL was launched in March 2021 through a \$13 million partnership between the Epworth Medical Foundation and the Snowdome Foundation.

In the first six months of becoming fully operational, the first patient had undergone a stem cell transplant. At the end of 2024, 35 patients have received a stem cell transplant

The first industry sponsored CAR T-cell clinical trial at ECISL began patient recruitment in February 2024, with the first CAR T-cell patient treated in April 2024. Eight patients have been enrolled, with six treated and two awaiting treatments. This trial uses 'allogeneic' CAR T cells from healthy donors, genetically modified for treatment of patients with non-Hodgkin lymphoma.

The importance of clinical trials and 'making hope real' is demonstrated in the journey of the first patient treated in this trial. In December 2023, a patient with diffuse large B-cell lymphoma started standard front-line therapy but experienced only a partial response. By April 2024, the disease had progressed becoming refractory to standard treatment. Eligible for the CAR T-cell clinical trial at ECISL, the patient was enrolled in April of the same year. The patient achieved early remission at 30 days and maintained complete metabolic remission on the 90-day PET scan, showing no signs of lymphoma. The patient reported improved quality of life and no evidence of disease progression.

“The first CAR T-cell clinical trial represents a new vanguard in CAR T-cell therapy because the cells are derived from healthy donors. This circumvents core complexities: time to treatment, cost of manufacturing, availability of therapy and health of the therapeutic T-cell product. This is a very exciting trial and we look forward to more excellent results,” said Dr Salvatore (Sam) Fiorenza, Deputy Medical Lead for Cell Therapies at ECISL.

The donor CAR T cells are manufactured in California and then shipped to a state-of-the-art, purpose-built laboratory complex that forms part of the ECISL.

Work continues to develop a point-of-care CAR T-cell clinical trial protocol to produce cancer-fighting immune cells. Using point-of-care technology to produce CAR T cells can reduce manufacturing costs, decrease the time to treatment for patients, and enable researchers and clinicians to rapidly translate science to point-of-care, improving patient outcomes and treatment options.

Professor Miles Prince AM, Director of Molecular Oncology and Cancer Immunology at the ECISL, stated, “This is a once in a lifetime opportunity to change the face of how cell therapies can be delivered to our patients.”

Supported by a group of generous donors, the ECISL is testament to the power of a philanthropic vision that drives innovation and change, with Australian blood cancer patients as the beneficiaries.

2024 Snowdome Fellowship

Optimising Immunotherapy for Aggressive Lymphoma



Dr Adrian Minson

In 2024, the Snowdome Fellowship for Optimising Immunotherapy for Aggressive Lymphoma commenced, led by Professor Michael Dickinson and Fellow, Dr Adrian Minson. This research looks at aggressive lymphoma, particularly diffuse large B-cell lymphoma and mantle cell lymphoma. These lymphomas are types of non-Hodgkin lymphoma (NHL) and are difficult to cure after relapse. Both cause significant morbidity and mortality in Australia and globally.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) globally, and Australia's sixth most common cancer. Approximately two-thirds of patients are cured by frontline chemotherapy, the current standard-of-care treatment. This leaves about one third needing second or subsequent lines of therapy. More than half of relapsing patients will die from their lymphoma.

Second and third-line therapy for DLBCL includes autologous stem cell transplantation (stem cells harvested from the patient) or Chimeric Antigen Receptor T-cells (CAR T-cells). These therapies are expensive and sometimes poorly tolerated. Avoiding relapse after frontline therapy is important, as is inducing a complete remission before planned stem cell transplantation.

Mantle cell lymphoma (MCL) accounts for roughly 15 per cent of NHL. Generally considered incurable, most patients relapse after front-line chemotherapy. Apart from allogeneic transplantation (using a donor's stem cells instead of the patient's own cells), which may only cure a third of patients and is unsuitable for most, it is not curable when relapsed. After the first relapse, the prognosis of mantle cell lymphoma is very poor.¹

Dr Minson, appointed as fellow for this study, is a Clinical and Laboratory Haematologist and PhD candidate under Professor Dickinson's supervision at the Peter MacCallum Cancer Centre in Parkville, Melbourne.

The four trials, TARMAC, GoIDiLOX, COALITION and EpcorSandwich, provided 180 Australian blood cancer patients, diagnosed with high-risk aggressive lymphoma, an opportunity to receive world-first novel combination treatments.

Dr Minson led the analysis of primary trial data from the TARMAC trial and the collaboration on correlative science, published in the peer-reviewed journal, Blood.² Publication in such an esteemed journal is a significant achievement.

The TARMAC trial explored combining immunotherapy (CAR T-cell therapy) with targeted therapy (BTK inhibitor) for relapsed/refractory MCL.

Patients with relapsed or refractory MCL, especially after targeted therapy, have poor prognosis with available treatments. The trial tested this novel combination to improve outcomes. The synergistic combination therapy enhanced each treatment's effectiveness. Dr Minson's analysis led to further trials investigating new targeted cellular immunotherapies (bi-specific antibodies) with other treatments, activating the immune system against cancer cells.

The COALITION trial explored frontline combination therapy for DLBCL, combining a T-cell activating immunotherapy (Glofitamab) with chemotherapy. This large trial included a world-first combination.

Having received the ASH-HSANZ Abstract Achievement Award at the 2024 American Society of Hematology (ASH) conference, Dr Minson presented the COALITION results at ASH that same year. The study showed high rates of deep, durable responses in high-risk patients. Over 85 per cent remained free from lymphoma progression after two years, a major milestone towards a cure.

The GoIDiLOX trial built on previous successes, investigating pirtobrutinib (new BTK inhibitor) with Glofitamab for relapsed/refractory MCL patients without conventional options. This global first trial is recruiting across 10 Australian sites, with results expected mid-2025.

The ongoing Epcor-Sandwich trial combines a bi-specific antibody with chemotherapy for relapsed DLBCL. It is recruiting across Australia and New Zealand, with an Auckland site opening soon.

These trials have shown combination therapies are highly effective for aggressive lymphoma patients with poor prognosis. The evidence aims to support TGA approval and PBS listing. The new therapy class could be accessible in most hospitals, rapidly initiated, and cost-effective.

Snowdome is delighted to support this world-first research to accelerate next-generation treatments. After initial Snowdome funding, Professor Dickinson and Dr Minson have leveraged significant additional funds.



Professor Michael Dickinson

1. Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, Anderson MA, Ritchie D, Tam CS, Seymour JF. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. *Lancet Haematol* 2023;10(2). <https://pubmed.ncbi.nlm.nih.gov/36725119/>.
2. Minson A, Hamad N, Cheah CY et al. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. *Blood*. 2024, 143(8):637-684. DOI <https://doi.org/10.1182/blood.2023021306>

2024 Gunn Family Haematology Fellowship

Personalised immunotherapy for the treatment of AL amyloidosis

In April, and with continued funding from the Gunn Family Foundation, Snowdome Foundation invited applications for a haematological research project to accelerate clinical trials for amyloidosis patients.

This fellowship was awarded to Muhammed B. Sabdia, a final year PhD student at Mater Research Institute, University of Queensland.


Muhammed's research focuses on a personalised immunotherapeutic approach to eradicate diseases such as AL amyloidosis and other rare blood diseases.

AL amyloidosis, affecting 320 Australians annually¹, is caused by clonal plasma cells secreting misfolded immunoglobulin light chains forming amyloid fibrils, leading to organ failure and death.

Muhammed decided to focus on AL amyloidosis due to poor patient outcomes and limited research. New therapies for AL amyloidosis are needed to improve clinical outcomes. Using methodologies from his PhD, Muhammed aims to develop an immune-based approach targeting a patient's dysfunctional plasma cells.

Collaborating with the BASE mRNA facility, Muhammed will design personalised mRNA vaccines to direct T cells to target neoantigens on plasma cells. This enables T cells to eradicate disease-causing plasma cells, promoting immunosurveillance and remission. Muhammed's research shows immunoglobulin genes contain numerous targetable neoantigens.

"This fellowship will help me develop expertise to advance understanding and treatment of rare blood disorders. My methodology is transferable to blood cancers, fostering collaborations with researchers and clinicians locally and internationally. I am grateful to the Gunn Family and Snowdome Foundation for this opportunity, hoping to improve outcomes for blood disorders and cancers," said Muhammed.



Muhammed B. Sabdia

This approach aligns with Snowdome's mission of accelerating next-generation treatments for Australian blood cancer patients.

The Gunn Family Haematology Fellowship is a three-year project. Muhammed aims to translate his research into clinical trials, possible due to the support of the Gunn Family Foundation.

Jackie Haintz, representative of the Gunn Family Foundation added, *"I hope no one has to hear their blood cancer is incurable. I'd like every person to have the opportunity to live a long, fulfilling and happy life with their family and friends. My family's Foundation is delighted to support Muhammed in his research, particularly given my own amyloidosis diagnosis."*

1. Wisniewski, B. et. al. The epidemiology of amyloidosis in Australia. Amyloid. 2019

International Partnerships and Collaborations

Snowdome Foundation continues to have the privilege of fostering partnerships between donors who wish to make a real difference to the lives of those affected by blood cancer and with the researchers and clinicians who can make it possible.

Sometimes partnerships are created for deeply personal reasons. This is true for the generous support received from the Gillespie Family Foundation for Associate Professor Paul Beavis' internationally recognised research project into multiple myeloma.

In late February 2024, Melbourne based lawyer Philip Colman, was diagnosed with multiple myeloma and AL amyloidosis (amyloid light chain or primary amyloidosis) - a rare incurable disorder. The AL amyloidosis severely compromised his heart and kidneys. Philip's condition initially deteriorated and he was admitted to hospital, where his condition then stabilised when he was discharged 4 weeks later.

For the next 6 months Philip received weekly immunotherapy and chemotherapy treatments at the Epworth Freemasons as well as undergoing stem cell harvesting in preparation for a possible future stem cell transplant.

By September 2024, Philip was in full remission and was able to increase his workload and exercise regime that included long walks, personal training and competitive sailing. In just over 10 months, Philip says he is "feeling good and back to normal". He now undergoes monthly immunotherapy maintenance.

Philip feels indebted to his medical team headed by Professor Miles Prince AM for the treatment and support he has received. Philip has said, "I was truly thrown a lifeline by Miles. I dodged a bullet. Were it not for his expertise and research into unique treatments, I would not be here today to tell my story. If I had myeloma 10 years ago, it would be a very different story."

Philip's sister and brother-in law, Lesley and Roger Gillespie, were impressed with Professor Prince AM's diagnosis, treatment and care and the work that Snowdome undertakes to improve treatment options and outcomes.

Lesley says, "While there are many worthy causes to support, our involvement with Snowdome is very meaningful. It is very personal given my brother's illness and if we can give a dollar and it can help others, it is something we are deeply committed to."

Roger has applauded the work of Snowdome in championing research into multiple myeloma and other blood cancers. While they remain private about their funding, Roger says, "we hope through our support we can encourage others to donate and fund the truly life-changing work of blood cancer researchers. The challenges are great but supporting these brilliant minds will fast-track more ground-breaking discoveries."

Thanks to the very generous donation from the Gillespie Family Foundation, a collaborative grant was awarded to Associate Professor Paul Beavis, a group leader based at the Peter MacCallum Cancer Centre (PMCC). The grant is an international collaboration between the prestigious Leukemia & Lymphoma Society (LLS) in the USA and the Snowdome Foundation, through the Translational Research Program (TRP). The Australian TRP recipients undertake innovative research projects that propose novel approaches to the prevention, diagnosis or treatment of blood cancers which show high promise for translating basic biomedical knowledge into clinical application.

Australasian Lymphoma Alliance

Snowdome proudly supports the Australasian Lymphoma Alliance (ALA).

The ALA is a collaboration of lymphoma clinicians who share research, practice and findings to better shape the care of lymphoma patients. Members range from registrars and nurses through to pharmacists and professors from haematology, oncology and radiology backgrounds.

In 2024, Dr Pietro Di Ciaccio took over from Professor Chan Cheah, as Chair of the ALA. Dr Di Ciaccio now leads a group of 146 members including six clinicians in New Zealand, three in Singapore, one in Japan and an Associate Member in Sri Lanka. All Australian states are represented, ensuring clinicians can easily access expert advice and opinions in determining diagnosis and treatment pathways for lymphoma patients.



Achievements for ALA members in 2024 include:

- 4 published papers in medical literature
- 1 research project presentation at the HSNZ Blood Conference (BLOOD)
- 2 new consensus practice statements published for:
 - marginal zone lymphoma; and
 - follicular lymphoma
- Over 70 patient cases presented at the Australasian T-Cell Lymphoma Network fortnightly eGrand rounds
- 50 members contributed to abstracts presented at the European Hematology Association conference
- 81 members contributed to abstracts presented at the American Society of Hematology conference (ASH), with 19 oral presentations
- 82 members contributed to abstracts presented at the HSNZ Blood Conference in Brisbane, with 26 involved with oral presentations

In July 2024, Dr Carrie van der Weyden chaired an ALA webcast with international speaker Professor Tim Illidge, Cancer Research UK and Professor Miles Prince AM on recent updates in the diagnosis and management of patients with peripheral T-cell lymphoma (PTCL).

An educational meeting exploring the Chronic Lymphocytic Leukaemia Australasian Consensus Practice Statement was also held in July 2024.

In October 2024, another successful lymphoma interest group breakfast was held during the Blood Conference in Brisbane. Co-hosted with the Lymphoma and Related Diseases Registry (LaRDR) and Lymphoma Australia, the event was attended by 75 guests with a small number joining virtually.

The ALA continues to improve outcomes for lymphoma patients through the collaboration and sharing of expertise, experience and knowledge. Since the ALA was formed, there has been close to 30 publications by early career researchers, 15 educational webinars, 11 consensus practice statements and four breakfast meetings held with LaRDR and Lymphoma Australia.

Major Donors, Trusts, Foundations and Estates

The Snowdome Foundation gratefully acknowledges the following Major Donors, Trusts, Foundations and Estates for their generous contributions in 2024 and for making hope real for Australians living with blood cancer.

Major Donors

- Peter & Sarndi Addison
- Andrew & Anna Baird
- Jeffrey Browne
- Peter & Kim de Winter
- Helen & Tony Gandel
- Roger & Lesley Gillespie
- Peter & Rae Gunn
- Tim & Aimee Gurner
- Mike & Jackie Haintz
- Dr George Klempfner & Yolanda Klempfner AO
- Tom & Lorelle Krulis
- Drew & Debbie Lean
- Harvey & Janette Lewis
- Ian & Jane Mandie
- Helen Nicolay
- Rosemary Pitt
- Sietel Limited – Mr Richard Rees
- Ian & Virginia Rehfish
- Graham Smorgon AM & Annette Smorgon
- Rodney & Ann Smorgon Family
- Rob & Lou Tandy
- David Thurin AM & Lisa Thurin
- Hendrikus & Debbie Verhagen
- Bruce Wilson
- Russell & Diane Withers
- Debra Wittner
- Philip & Trix Wollen
- Yueh-Chuan Yu

Foundations

- Broomhead Family Foundation
- The Calvert-Jones Foundation
- Gillespie Family Foundation
- Goldman Sachs Gives
- Rae and Peter Gunn Family Foundation
- GURNER™ Foundation
- The Paula and Jack Hansky Charitable Fund
- Harbig Family Foundation
- GP Harris Foundation
- Jan and Robert Lyng Charitable Fund
- The McNamara Family Foundation
- Morris Family Foundation
- Mostyn Family Foundation
- The Samuel Nissen Charitable Foundation
- Percy Baxter Charitable Trust
- The Pratt Foundation
- Silberscher Family Foundation
- Weinman Charitable Fund
- The Wolf Foundation

Estates

- Estate of Marjorie May Kingston
- Estate of Dianne Bronwyn Mitchell
- The Wolf Foundation

Fundraisers

Snowdome would like to acknowledge Geoff Nyssen (MY Mount Eliza Fun & Run Festival), Aaron Campbell and the family and friends of Tim Sim and the Black Rock Football Club for their wonderful fundraising efforts in 2024.

We also extend our heartfelt thanks to the numerous individuals and families who donated or raised funds in memory of a loved one someone or in lieu of gifts for us throughout the year and those who wish to remain anonymous.

Since 2010, Snowdome has supported the following researchers, clinicians and individuals

We are extremely proud to support exceptional Australian researchers and clinicians and their commitment to advancing next generation blood cancer treatments.

Over the last 14 years, Snowdome has funded 71 multi-year research projects, enabling 101 research positions. We are delighted to showcase their efforts and remain committed to promoting collaborations between researchers, clinicians and individuals who are passionate about contributing to blood cancer research.

A/Prof Mary Ann Anderson	James Hicks	Prof David Ritchie
A/Prof Paul Beavis	Prof Ricky Johnstone	Dr David Ross
A/Prof Piers Blombery	A/Prof Lev Kats	Prof Andrew Roberts AM
A/Prof Charles de Bock	A/Prof Melita Kenealy	Muhammed B. Sabdia
Prof Richard Boyd	A/Prof Amit Khot	Prof Jake Shortt
Dr Nicole Brooks	Tracy King	Prof Andrew Spencer
Dr Imogen Caldwell	Dr Hansen Kosasih	Prof Jeff Szer AM
Prof Chan Cheah	Dr Jamie Kuzich	Dr Peter Tan
Dr Edward Cliff	Emily Li	Dr Siok Tey
Dr Patrick Connerty	Prof Richard Lock	A/Prof Daniel Thomas
Dr Katherine Cummins	Dr Kylee Maclachlan	Dr Ella Thompson
Prof Mark Dawson	Prof Ravi Majeti	Dr Joshua Tobin
Dr Carie van der Weyden	Dr Jacek Marzec	Prof Judith Trotman
Dr Jennifer Devlin	Dr Adrian Minson	Dr Ashwin Unnikrishnan
Prof Michael Dickinson	Dr Elizabeth Moore	Dr Kate Vandyke
Dr Pilar Dominguez	Prof Charles Mullighan	Dr Meaghan Wall
Dr Katie Fennell	Dr Niles Nelson	Prof Andrew Wei
Dr Salvatore (Sam) Fiorenza	Prof Stephen Nutt	A/Prof David Westerman
Dr Lucy Fox	A/Prof Jane Oliaro	Dr Simon Willis
Dr Clare Gould	Dr Michael Osborn	Dr Colin Wood
Dr Gareth Gregory	Dr Anna Piggin	Dr Simon Wu
Prof Sean Grimmond	Prof John Pimanda	A/Prof Costas Yannakou
A/Prof Carolyn Grove	Prof Miles Prince AM	Dr Paul Yeh
Dr Belinda Guo	Dr Indu Raman	Dr Jessie Zhao
Prof Eliza Hawkes	Dr Matthew Rees	

A Year of Exceptional Research Grant Awards

Through the incredible generosity of our philanthropic donors and partners, Snowdome Foundation has the ability to provide Australia’s best clinicians and researchers with much-needed funding to support their commitment to discovering next-generation diagnostic tools and treatments.

In 2024, Snowdome awarded the following grants to pursue innovative approaches to blood cancer research and treatments:

- LLS-Snowdome Foundation Translational Research Program - Associate Professor Paul Beavis
- Cannon Family Travel Grant - Dr Edward Cliff
- Cannon Family Travel Grant - Dr Hansen Kosasih
- Gunn Family Haematology Fellowship - Muhammed B. Sabdia



A/Prof Paul Beavis



Dr Edward Cliff



Dr Hansen Kosasih



Muhammed B. Sabdia

Snowball 2024

On Thursday 10 October 2024, our fundraising event Snowball returned to the splendour of the Malvern Town Hall. Guests were invited to immerse themselves in “Snowball Cucina” to enjoy a delicious dining experience created by celebrated chef Guy Grossi and the team from Cookes Food & Events.

The event raised an incredible \$670,000! Our best result to date.

Snowball raises funds to positively impact the lives of blood cancer patients in Australia, helping them to live longer, better lives. The funds raised in 2024 are being directed to provide access to two, life-saving drugs for T-cell and B-cell lymphoma patients.

These drugs are currently not subsidised by the Australian Government and can cost patients more than \$20,000. Our incredible donors and guests helped raise money that goes directly to patients in need, saving lives through access to these ‘saviour’ drugs and providing an evidence-based case to advocate for the Australian government to subsidise them.

Speaking at the event, Snowdome Chief Executive Kirstee Macbeth showcased the Foundation’s significant impact since inception and the need to continue to activate and advocate to enable a paradigm shift in blood cancer treatment in Australia.

Lymphoma patient advocate Tahli Batkilin moved us all as she spoke about her journey with stage 4, aggressive B-cell lymphoma and her subsequent remission following subsequent remission following the approved Yescarta® CAR T-cell therapy. Tahli was the first patient in Australia to receive this treatment.

However, as Professor Miles Prince AM, Snowdome co-founder and director highlighted, others are not so fortunate. As a clinician, Miles sees first-hand that some blood cancer patients are dying without access to appropriate drugs. Snowball raised money to provide qualifying T-cell and B-cell lymphoma patients access to specific drugs.

Snowball could not happen without the very generous support from our Event Partners: Town Square, Dann Event Hire and AV Dynamics and the support of our Event Sponsors: Balter Brewing Company, Cono Gelateria, Décor It Studio, DUSC Studio, Forty Spotted Gin, Gilbert Family Wines, Green Event, Hartshorn Distillery, IFAS Group, Mad For You Creative, Pino’s Fresh Produce, Point Leo Estate, Sanpellegrino, Scotchmans Hill Estate, Slide Productions, Vranken-Pommery, Wojo Signs and Wynns.

Our most sincere thanks to our dedicated Snowball Organising Committee who so capably brought the event together. Pennie Callaghan (Chair), Helen Gandel, Kirstee Macbeth, Lauren Frazer, Georgia Larkins, Elian de la Rosa Gomez, Vanessa Cohen and Georgie Stayches.

We are immensely grateful to our donors, event partners and sponsors who support our mission to accelerate next-generation blood cancer treatments, helping us raise these vital funds.



Snowdome Honorary Patron

As Honorary Patron of the Snowdome Foundation, Sam Neill continues to inspire T-cell lymphoma patients across Australia and the world, with the hope of accessing new and groundbreaking therapies.

Snowdome is singular in our focus to provide access to new and innovative treatments, and getting them to Australian blood cancer patients faster, in particular CAR T-cell therapy and immunotherapies. However, for some blood cancer diagnoses, there isn't yet a suitable CAR T-cell therapy developed, or the patient's disease is not able to be controlled enough for the application of this treatment to be effective. This is the case for patients with T-cell lymphoma.

For patients who do not respond to chemotherapy, the average survival rate is low. However, in 2009, a new treatment for T-cell lymphoma was approved by the Food and Drug Administration (FDA) in the USA. This new drug interferes with the growth of cancer cells, which are eventually destroyed by the patient's own body. In 2013, the Therapeutic Goods Administration (TGA) approved its use for T-cell lymphoma patients in Australia albeit in certain circumstances. Yet, today the therapy remains unsubsidised by the Pharmaceutical Benefits Scheme (PBS) and out of reach of many.

In 2022, after being diagnosed with a rare form of blood cancer, angioimmunoblastic T-cell lymphoma, Sam Neill underwent chemotherapy. While this conventional therapy did not improve his condition, Sam was fortunate to gain access to the new treatment. Over two and a half years later, we are delighted that Sam continues to be in remission.

Sam is a living testament to Snowdome's mission to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives.

We recognise that medical practitioners often prescribe non-PBS listed therapeutic products that can only be funded by patients themselves.

Recently, Snowdome raised funds to support access to new therapeutic treatments for patients with T-cell and B-cell lymphoma.


Snowdome Foundation's co-founder, Prof Miles Prince AM says,

"in providing support to patients who cannot afford these therapies and working with clinicians across Australia, Snowdome will be able to develop a strong, indisputable, evidence-based case for the Australian Government to subsidise these therapies and save Australians who have no other option."

We are very honoured that Sam is our Honorary Patron and continues to advocate for blood cancer patients.

In Sam's words,

"the support that the Snowdome Foundation is giving to blood cancer patients with very poor prognoses is immeasurable and I am happy to help where I can."



2024 Events

Inaugural Snowdome Ladies Luncheon

On Thursday 7 March 2024, Snowdome hosted the inaugural Snowdome Ladies Luncheon at the Commons Collective.

The lunch coincided with International Women's Day, shining a spotlight on two clinical researchers working in the fields of blood cancer and immunotherapy.

Associate Professor Jane Oliaro, Peter MacCallum Cancer Centre and Dr Nicole Brooks, Epworth Healthcare, shared their inspiring work and how it is shaping the future of blood cancer research and treatments.

Their passion and commitment drive innovation and bring hope to thousands of Australians affected by blood cancer.

Thank you to everyone who attended and to these incredible women and their tireless efforts in advancing medical science.

Cumming Dinner

On 26 March 2024, the Snowdome Foundation hosted an intimate dinner in honour of Canadian businessman and philanthropist, Geoff Cumming and Professor Sharon Lewin, Director, The Peter Doherty Institute for Infection and Immunity and the Cumming Global Centre for Pandemic Therapeutics at Cecconi's in Toorak.

In 2022, Geoff and his wife, Anna donated \$250 million to the University of Melbourne to establish the Cumming Global Centre for Pandemic Therapeutics within the Doherty Institute. This transformational gift is the largest philanthropic donation to Australian medical research.

As guest speaker, Geoff shared his and his family's personal philanthropic journey, which was insightful, inspiring and reinforced the power of what can be achieved when focusing on a long-range future for all mankind.

Hearing about his path to giving and the significant ways it has shaped his life was a reminder of how individual commitment can amplify our collective mission, and what the Snowdome Foundation aims to achieve with blood cancer patients.

We thank Geoff once again for sharing his story and the transformative power of philanthropy.

Making an Impact

Our annual educational event 'Making an Impact' returned on 16 May, a continuation of our series designed to highlight and showcase the latest in blood cancer research, technologies and next-generation treatments. In 2024, Making an Impact focused on myeloma.

Professor Miles Prince AM, Snowdome co-founder, board director and an internationally recognised haematologist, presented on the importance of unlocking the immune system in the treatment of blood cancer, focusing on a ground-breaking therapy known as Chimeric Antigen Receptor (CAR) T-cell therapy. This treatment involves collecting T cells from the patient, modifying them to target cancer cells and reintroducing them to the patient's body. The modified T cells then seek and destroy cancer cells with unparalleled precision.

Associate Professor Jane Oliaro then presented her cutting-edge CAR T-cell research on novel gene editing technology at the Peter MacCallum Cancer Centre (PMCC).

We also heard from two myeloma patients, Geoff Nyssen, patient advocate, and Jeffrey Browne, president of the Collingwood Football Club. Whilst Jeffrey has been newly diagnosed, Geoff has been living with myeloma for 10 years. Their journeys through the diagnosis and treatment of myeloma offered an insight into the human side of medical advancements.

Geoff Nyssen was diagnosed with myeloma in 2014 and despite undergoing multiple treatments, he experienced relapses after each one. Having exhausted all other options, Geoff travelled to Seattle, USA in December 2023, to receive CAR T-cell therapy, a treatment not yet approved in Australia for his specific type of myeloma. Returning home in February 2024, Geoff is now in complete remission following this treatment and cancer-free for the first time in a decade.

Following Jeffrey Browne's myeloma diagnosis, he underwent a series of treatments culminating in a stem cell transplant. Jeffrey's journey became a powerful call to action and he is now a steadfast advocate, championing equitable access to CAR T-cell therapies.

The evening was a successful showcase of Snowdome's commitment to making a tangible impact on the lives of blood cancer patients in Australia.

Cannon Family Travel Grants

The Cannon Family Travel Grants provide Australian blood cancer researchers with the opportunity to travel to broaden their knowledge, exchange ideas, establish collaborations and bring back valuable insights that can contribute to the advancement of blood cancer research in Australia.

Dr Patrick Connerty

Dr Patrick Connerty was awarded a grant to attend the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.



This international event brought together over 1,200 participants from 41 countries including academics, scientists, and industry leaders to explore the latest advancements in drug development, target selection, and molecular biology.

For Dr Connerty, a standout session from the symposium was a keynote presentation by Dr Jennifer Wargo from the MD Anderson Cancer Centre who discussed the role of the microbiome in cancer. The session was particularly relevant to Dr Connerty's research, leaving him with several actionable strategies he can use to improve and refine his work as a postdoctoral researcher in the Leukaemia Biology group at the Children's Cancer Institute in Sydney.

Emphasising the importance of the microbiome, Dr Connerty said, "the emerging research suggests that the microbiome may significantly influence cancer progression and treatment responses, potentially making it a crucial component of future therapeutic strategies. This perspective has opened my eyes to an additional layer of complexity to cancer treatment which we have never addressed in our research".

Amongst many other learnings from the conference, Dr Connerty was inspired by a presentation highlighting the importance of creative problem-solving in overcoming laboratory challenges, a lesson that has encouraged him to think more innovatively about tackling obstacles in his research. Overall, Dr Connerty shared that his attendance at the conference was immensely impactful, saying "it not only validated [his] current research strategies but also provided fresh insights and inspiration, driving [him] to push forward with even greater confidence and vision for [his] research program".

Dr Jennifer Devlin

Dr Jennifer Devlin of Peter MacCallum Cancer Centre travelled to Heidelberg, Germany to attend the European Molecular Biology Laboratory Conference in August.



The conference aims to advance the transcriptional regulation research field through the sharing of current unpublished research findings, description of new technologies and lab methodologies, and formation of new collaborations through networking.

Dr Devlin attended the conference to present a poster on her research and to develop important contacts that could benefit her research into the future. Dr Devlin's poster received valuable feedback and presented an opportunity for an international collaboration.

Of significant interest to Dr Devlin's work were key oral presentations from Prof Ali Shilatifard (Northwestern University, US), Prof Yang Shi (Ludwig Centre for Cancer Research, Oxford, UK) and A/Prof Cigall Kadoch (Dana Farber Cancer Institute, Boston, US).

Dr Devlin told us, "Prof Shilatifard's presentation was of particular relevance to my work and to blood cancer research. For more than 25 years, his lab has studied components of the transcriptional machinery that are frequently mutated in blood cancers, particularly acute myeloid leukaemia (AML), with many of the experiments performed in his lab using the same AML cell lines that I use for my own research. This has made me reflect on how I could incorporate these approaches into my own research project. He also described a new technology his lab has employed that may be applicable for my own research".

Dr Devlin plans to apply the knowledge she gained at the conference to a new project she is leading to test whether combinations of transcriptional inhibitor and epigenetic inhibitors will provide better therapeutic outcomes in aggressive acute-myeloid-leukaemia cells.

Snowdome would like to thank the Cannon family for their continued contribution to the advancement of blood cancer research in Australia.

Environmental, Social and Governance Compliance

The Snowdome Foundation is committed to creating a positive impact in all areas of our business

Our Environmental, Social and Governance (ESG) statement reflects our dedication to responsible, sustainable and ethical practices and behaviours.

Environmental

Acknowledging our environmental responsibilities, we are committed to minimising our carbon, water and waste footprint and promoting sustainable practices that reduce impact on the environment.

Our strategies include encouraging the use of public transport to and from the workplace, limiting hard copy printing, using environmentally friendly paper, recycling and separating waste, and using environmentally friendly cleaning products. At our events, we minimise food wastage and donate any usable produce to food rescue and give usable floral decor to guests to minimise wastage. In addition, we ensure all unused beverages are stored for consumption at other subsequent events.

Social

We value diversity, equity and inclusion, fostering a safe, supportive and inclusive environment for our staff, directors, partners, researchers, clinicians, committee members and volunteers. These values are reflected in the following ways:

- The gender diversity of our board and executive is 55% female and 45% male; and
- We are proud that our organisation has been led by female Chief Executives since its establishment in 2010.

We have supported and embraced the integration of people with disabilities in our workplace. We have worked together with external employment services to provide employment opportunities for people with disabilities with outstanding results.

Governance

We have a strong governance structure with clear reporting lines and well documented and practiced policies and procedures for operations. We have a diverse and skills-based Board that work closely with the Executive, meet at least eight times per year and regularly assess finance and risk. We have multiple sub-committees that each have a charter and comprise external independent members, that meet at least three times per year and report to the Board. Our governance practices adhere to the highest ethical standards, ensuring transparency, accountability and responsible decision-making.

We are committed to continual review and improvement processes and engage external parties to audit and review financials and strategy. A reflection of our commitment in this area is the return of a clean audit in 2024.

Our rigorous adherence to cybercare is a priority for Snowdome with continuous review of all requirements to ensure the integrity and safety of the data we hold.

ESG principles are part of our core values to fulfill our mission to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives.

Financials 2023-24

The Snowdome Foundation is a leading not-for-profit organisation focused exclusively on raising funds to support translational research and clinical trials. Since inception in 2010, the Group has raised \$66 million for blood cancer research.

Snowdome Group has concluded Fiscal24 in a robust financial position that saw a balance sheet position with high levels of liquidity maintained and net assets exceeding liabilities by \$7.88 million. The net assets include \$6.15 million, which is being held to meet grants commitments into the short-term future.

Snowdome Foundation Limited (SFL) became Snowdome Group's primary operating and grant funding entity from Fiscal 23. The Group results showed a substantial increase in profitability in Fiscal24 up \$2.4 million with a surplus of \$0.6 million, compared to a deficit of \$1.8 million in Fiscal23.


Reported accounts show an operating surplus which can be attributed to moderate increases in fundraising events income and interest earnings combined with delayed phasing of grants expenditure. Overall, revenue decreased by 10 per cent during the financial year, balanced by a 40 per cent decrease in expenses due to \$1.7 million of FY24 committed grants expenditure now expected in FY25. Overall, expenses continued to be tightly managed.

Snowdome remains in a strong position to support its grants pipeline, with the majority of grants having fully funded commitments in place, and all grants having at least two years of prefunding committed.

Further, Snowdome has a financial reserve that covers one year's wages and operating expenses, equating to \$1.1 million. This provides assurance to all financial contributors that Snowdome is strongly positioned to ensure its ongoing financial viability and that donors can be confident that their donations will be invested as intended, in support of blood cancer research.


Since inception Snowdome has funded 71 research grants, enabling more than 101 research positions.

Revenue raised by Snowdome from Inception to the end of FY24: \$66 million.



Snowdome has had another successful year in maintaining all existing grants, as well as offering new grants during the fiscal year. During Fiscal24, a total of \$2.3 million of research grant funding was paid.


Research funded through Snowdome from inception to end of FY24: \$56 million.



At the end of FY24, 93 per cent of available funds had been granted.

Since inception, Snowdome has funded 71 research grants, enabling 101 funded research positions, across an amount of \$56 million.

Revenue received during the FY24: \$3.9 million.



Legal Structure

The Snowdome entity consists of Snowdome Foundation Limited DGR (Deductible Gift Recipient) Item 1 and Snowdome Limited DGR Item 2. As a result, the Snowdome entity can accept tax deductible donations from all donors including Private Ancillary Funds. As from Fiscal23, Snowdome Foundation Limited DGR1 entity became the principal group member in terms of fundraising for all new grant activity.

Governance

Throughout the year, the Snowdome Grants Committee reviews and recommends strategic projects to be funded. We are mindful that many of our grants are multi-year research projects. As such, we seek to fund them with multi-year donations to provide certainty of funds. We start the process by first attaining the donation commitment and then extending the grant commitment.

All grants provided have clear, measurable key performance targets which are reviewed every six months by the Snowdome Grants Committee.

The Snowdome Finance, Audit and Risk Committee oversees financial performance to minimise risk for the organisation.

Financial Year 2024 (FY24) Accounts

Snowdome's financial year accounts have been audited and submitted to the Australian Charities and Not-for-Profit Commission (ACNC).

Notwithstanding the general business uncertainties and rising inflation, Snowdome's donors generously supported us in Fiscal24. Snowdome received greater than expected philanthropic grants in Fiscal24 and coupled with tight expense control, resulted in a surplus for this financial year of \$601K.

Snowdome has continued to meet all grant commitments, with \$2.3 million invested in Australian blood cancer research grants in Fiscal24.

Highlights of the 2024 financial year include:

Pro Bono Support of \$388,891.

Snowdome continues to be well supported by our incredibly generous pro bono partners with a total of \$389K donated during the fiscal year.


We are very thankful for their ongoing commitment.

Granting of \$2.3 million to blood cancer research.

During the financial year Snowdome granted \$2.3 million.

As of July 2024, Snowdome has \$6.15 million in future grant commitments, all cash backed to be paid in future financial years.

Income breakdown financial year 2024



Expense breakdown financial year 2024



*Matched – Funding support matched by collaborative partners

**Directed – When Snowdome donations are paid directly to the administering organisation

***Other - Interest earned via Term Deposits and general miscellaneous income

Pharmaceutical grant funding for the Australasian Lymphoma Alliance has not been included in the figures above (\$107K)

Financials 2023-2024



Income Statement for the year ended June 30 2024	Snowdome Ltd ATF Snowdome Foundation (DGR2)	Snowdome Foundation Limited (DGR1)	Consolidated 2024	Consolidated 2023
Income (AUD\$)				
Donations	120	2,834,837	2,834,957	3,476,886
Fundraising events	—	753,952	753,952	510,606
ALA income	—	106,785	106,785	59,351
BCRWA income	—	0	0	232,617
Pro bono goods / services received	—	388,892	388,892	415,496
Interest	3,199	287,683	290,882	178,355
Other income	—	1,906	1,906	7,125
Total Income	3,319	4,374,055	4,377,374	4,880,436
Expenses (AUD\$)				
Grants to organisations	9,545	2,249,506	2,259,051	4,312,783
Fundraising events expense	—	235,111	235,111	96,206
Employee benefits expense	—	662,983	662,983	654,546
ALA expenses	—	87,496	87,496	70,863
BCRWA expenses	—	0	0	27,456
BCRWA distribution expenses	—	0	0	960,499
Pro bono goods / services expenses	—	388,891	388,891	415,496
Amortisation and depreciation expenses	1,504	15,669	17,173	8,204
Other expenses	705	133,180	133,885	145,766
Total Expenses	11,754	3,772,836	3,784,590	6,691,819
Surplus / (deficit) for the year	8,435	601,219	592,784	1,811,383

Statement of Financial Position As at 30 June 2024	Snowdome Ltd ATF Snowdome Foundation (DGR2)	Snowdome Ltd ATF Snowdome Foundation (DGR2)	Consolidated 2024	Consolidated 2023
Assets (AUD\$)				
Current Assets				
Cash & Cash Equivalents	97,527	7,796,259	7,893,786	7,198,145
Trade & Other Receivables	455	62,860	63,315	204,158
Total Current Assets	97,982	7,859,119	7,957,101	7,402,304
Non-Current Assets				
Plant & Equipment	—	2,852	2,852	3,536
Intangible assets	—	52,902	52,902	8,183
Total Non-Current Assets	—	55,754	55,754	11,719
Total Assets	97,982	7,307,600	7,414,023	9,371,584
Liabilities (AUD\$)				
Current Liabilities				
Trade & other payables	—	8,319	8,319	9,298
Provisions	—	30,284	30,284	29,623
Other Liabilities	—	—	—	6
Total Current Liabilities	—	38,603	38,603	38,927
Non-Current Liabilities				
Provisions	—	28,283	28,283	21,911
Total Non-Current Liabilities	—	28,283	28,283	21,911
Total Assets	—	66,886	66,886	60,838
Net Assets	97,982	7,847,987	7,945,969	7,353,185
Funds (AUD\$)				
Settled Sum	100	—	100	100
Retained Surpluses	97,882	7,847,987	7,945,869	7,353,185
Total Current Liabilities	97,982	7,847,987	7,945,869	7,353,185
Total Assets	97,982	7,847,987	7,945,969	7,353,185

Board of Directors

The Snowdome Board of Directors consists of twelve independent non-executive directors and one executive director. Our passionate, skilled and highly engaged directors bring diverse experiences and expertise from various industries and sectors.

They are our governing body, ensuring Snowdome realises its mission through responsibility for our strategic direction, establishing goals for management and achieving these through various committees. We also acknowledge the ongoing support of our board alumni.

The Snowdome Board of Directors would like to acknowledge and thank Michael Robertson who retired from the Board in 2024. The Board would also like to welcome Mark Inston and Anna Whitlam who joined the Board in 2024.



Mark Inston

Partner, Banking and Finance, Hall & Wilcox.

Mark is the Chair of the Snowdome Lymphoma Governance Committee and a member of Snowdome's Finance, Audit and Risk Committee, both positions he has held since 2019.

Mark joined the Board in October 2024.



Ms Amanda Jones
BAppSc Grad Dip IP
Law FIPTA

IP Professional and former Medical Scientist. Medical Research Future Fund (MRFF) Grant Proposal Manager, University of Melbourne. Amanda has a personal connection to blood cancer through her mother and sister.

Amanda joined the Snowdome Board in 2014.



John Nevins
BEcon GDipPubPol
MAICD

John is semi-retired and has previously worked in Victorian Local Government, Public Transport and the Victorian Public Service. John offers a personal perspective living with leukaemia.

John joined the Snowdome Board in 2023.



Dr Andrew Pascoe
MBBS

Executive Chairman of the Asia Pacific eHealth Group (APeHG).

Andrew joined the Snowdome Board in 2013.



John Salvaris
BEc CA CPA

Chairman. Partner of KPMG specialising in corporate tax matters for financial services organisations.

John joined the Snowdome Board in 2017 and became the Chairman in 2020.



Prof Richard Boyd
BSc (Hons) PhD

Chief Scientific Advisor of Cartherics Pty Ltd, a cancer immunotherapy company.

Richard joined the Snowdome Board in 2015.



Helen Buckingham
OAM
BA Dip Ed Grad Dip
Careers AICD Dip

Helen offers a personal perspective living with multiple myeloma since 2004. Helen was elected to the Legislative Council of the Victorian Parliament in 2002 and has been involved with Snowdome since its inception in 2010.



Helen Gandel

Pharmacist and philanthropist supporting a variety of community charities.

Helen joined the Snowdome Board in 2016.



Prof Miles Prince AM
MBBS (Hons) MD FRACP
FRCPA AFRCMA MACD
FAHMS

Blood cancer specialist and a Professor of Medicine at both Melbourne and Monash Universities, Professor/Director of Molecular Oncology and Cancer Immunology at Epworth Healthcare, Haematologist at the Peter MacCallum Cancer Centre and Director of the Epworth Centre for Immunotherapies & Snowdome Laboratories.

Miles is a co-founder of the Snowdome Foundation.



Grant Rutherford
BA Graphic Design

Co-founder and director of East of Everything.

Grant is Chloe Rutherford's father, for whose love of snowdomes (during her leukaemia treatment), the Foundation is lovingly named.

Grant is a co-founder of the Snowdome Foundation.



Rob Tandy
BSc MPC

Facilitator from the tourism, investments and property industries. Rob brings a personal perspective of blood cancer lived through his father's diagnosis of multiple myeloma.

Rob is a co-founder of the Snowdome Foundation.



Anna Whitlam
BBus (HR & Marketing)
GAICD

CEO, WhitlamCo. an APAC executive search and advisory firm specialising in the functions that build reputation, trust and stakeholder value.

Anna joined the Snowdome Board in 2023.

Executive



Our team is comprised of talented, generous and committed people, driven by making a difference to the lives of those affected by blood cancer.

In 2024, we welcomed new talented people into our team, enhancing our capabilities in administration, events, finance, fundraising and marketing. New team members bring with them a wealth of fresh perspectives and ideas to the Snowdome Foundation.

Kirstee Macbeth

Chief Executive
& Company Secretary



Tanya Jörgensen

Head of Operations



Margaret Dandis

ALA & ATCLN
Administration Manager



Elian de la Rosa Gomez

Engagement
Manager (Events)



Marlena Assenza

Executive Assistant



Jess Bucci

Marketing
& Communications
Coordinator



The Snowdome Foundation would like to extend a very special thank you to Cathy Rhodes, former Head of Operations & Finance. In August, after six years of service, Cathy left to follow her passion for travel. We thank her for her dedication, expertise and for truly making a difference to Australian blood cancer patients. Cathy left a lasting impression on Snowdome, and we remain ever grateful for her contributions.

We would also like to acknowledge and thank Vanessa Cohen, Dan Mars, Sue Hunt, Teodora Kusevska and Daniel Manning for their contributions to Snowdome during 2024.

Committees



Finance, Audit and Risk Committee

John Nevins
(Chair)

Jackson Considine

Mark Inston

Michael Robertson
(Retired in Oct 24)

John Salvaris

Foundation Advisory Committee

Andrew Pascoe
(Chair)

Ian Allen

Helen Gandel

Lisa Livis
(Joined Oct 2024)

Rob Tandy

James Wilson

Grants Committee

Prof. Richard Boyd
(Chair)

Amanda Jones
(Deputy Chair)

Helen Buckingham OAM

Dr Anna Kalff

Dr Olivia Milne

Dr Andrew Pascoe

Remuneration Committee

John Salvaris
(Chair)

Amanda Jones

Rob Tandy

Anna Whitlam

Lymphoma Governance Committee

Mark Inston
(Chair)

Prof. Chan Cheah

Dr Pietro di Ciaccio

Dr Gareth Gregory
(retired in March 2024)

Dr Greg Hapgood

Assoc Prof. Eliza Hawkes

Dr Anna Johnston

Prof. Miles Prince AM

Snowball Committee

Steering Committee
Rob Tandy
(Chair)

Helen Gandel

Dr Andrew Pascoe

Organising Committee
Pennie Callaghan
(Chair)

Vanessa Cohen

Lauren Frazer

Helen Gandel

Georgie Larkins

Snowdome Executive
Kirstee Macbeth

Elian de la Rosa Gomez

Partners & Collaborators

Supported
by Snowdome
Foundation



Collaborators

To advance blood cancer research and bring hope to Australian blood cancer patients, Snowdome Foundation is proud to collaborate with:



Children's Cancer Institute
Cure Cancer Australia
South Australian Health and Medical Research Institute (SAHMRI)
Haematological Society of Australia and New Zealand

Mater Research Institute
Mayo Clinic
Peter MacCallum Cancer Centre

Monash University
Stanford University
University of Adelaide
University of Melbourne
University of New South Wales
University of Queensland

Pro bono partners and supporters

The ongoing generosity of these organisations allows the Snowdome Foundation to optimise the allocation of funds towards the advancement of medical research for blood cancer.



CHRIS BUDGEON



TOWN SQUARE



Snowball 2024

Snowball 2024 raised an incredible \$670,000. The funds raised will be directed to provide access to two, unsubsidised, life-saving drugs for T cell and B cell lymphoma patients. We extend our heartfelt thanks to our event partners and supporters that made the night such a success.

Event Partners

TOWN SQUARE

dann
event
hire.



Event Sponsors



ANTON



greenevent



A Legacy of Hope



Gillian Hund leads a life filled with purpose and passion.

From her early days as a school teacher to her 25-year career in the publishing business, Gillian has never shied away from taking on new challenges. But it was a deeply personal tragedy that truly defined her philanthropic journey and inspired her to create a lasting legacy.

Gillian's life changed when her older sister was diagnosed with acute myeloid leukaemia (AML) and very sadly passed away at the age of 37. The loss was devastating, but it also ignited a commitment to support blood cancer research. Today, Gillian has become a fervent advocate for research funding.

Gillian often thinks about how much the field of blood cancer research has advanced. Reading about the new treatments and improved patient outcomes gives her hope and enables her to believe that it is crucial to support this ongoing research.

In her pursuit to make a difference, Gillian enrolled in a Master's program in Philanthropy at Swinburne University. A decision that broadened her understanding of giving and charity work. She later joined a philanthropic board and co-launched an initiative in 2014 where individuals collectively donate to support vulnerable women and children. The program has been a success, underscoring the impact of collective effort in philanthropy.

"Philanthropy is something that is very close to my heart. We can all give in different ways, and it is such an important part of our lives. The friendships and connections you make, and the deeper understanding of the issues, give back so much more than what you can give."

Gillian's dedication to philanthropy extends beyond her active involvement. She has made a decision to include a bequest to the Snowdome Foundation in her will. It is a decision driven by both her personal loss and a desire to see further advancements in treatments for blood cancers.

Gillian's message to others is clear: if you believe in supporting a cause, take the necessary steps to include it in your will. She advises that a lot of lawyers do not ask about bequests, so it is important to take the initiative. Making a legal provision ensures that your wishes will be honoured.

Her philanthropic spirit, shaped by both professional experience and personal tragedy, serves as an inspiration.

Through her bequest to Snowdome, Gillian hopes to contribute to a future where blood cancer can be cured. Her journey is a testament to the enduring power of love and loss, and the remarkable impact one person can have in the cure for blood cancer.

Dedication

The Snowdome Foundation is dedicated to all those that have been touched or affected by blood cancer.

The Snowdome Foundation would like to recognise and honour the memory of **Edith Greiman**. Edith's very generous support of Snowdome advanced vital blood cancer research, providing hope to many Australian blood cancer patients. Edith was a very special member of the Snowdome family and will be sadly missed.



Sadly, in 2024, Snowdome bid farewell to more cherished members of our family. We would like to honour the memory of Richard Smallwood AO, first Chair of the Snowdome Grants Committee.

What's in a Name?

The Snowdome Foundation is named after Chloe Rutherford.


Diagnosed with leukaemia in 2007, Chloe seemingly beat the disease only to relapse and die of complications arising from pneumonia in 2009. She is survived by her loving mother, beautiful sister and her adoring dad, Grant Rutherford, who is a big part of Snowdome.

The Foundation's unusual name emerged from a case of mistaken identity rather than a flash of inspiration, but it's entirely appropriate.

On the first of many visits to the Royal Children's Hospital in Melbourne, Chloe thought she saw a gift shop, with snowdomes from all over the world adorning its glass walls.

In fact, it was the nurses' station in the middle of the ward, but to Chloe it was beautiful and magical, and like all things beautiful, she just had to have a snowdome of her own. As she bravely battled her blood cancer, more and more snowdomes appeared; gifts from family, from friends both old and new and from the nurses who cared for her.

So, when the Foundation was conceived, it seemed only fitting to name it after Chloe's love of snowdomes.



SNOWDOME, the Snowdome logo and 'Making Hope Real' are trademarks of Snowdome Foundation Limited.

Snowdome Limited
(DGR 2) - ABN 26 239 780 877

Snowdome Foundation Limited
(DGR 1) - ABN 79 624 141 117





Snowdome
Foundation™

